Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2023-09-28
- Target Recruit Count
- 78
- Registration Number
- NCT03829462
- Locations
- 🇫🇷
Centre Antoine Lacassagne, Nice, Alpes-Maritimes, France
🇫🇷Centre François Baclesse, Caen, Basse-Normandie, France
🇫🇷Hôpital Pontchaillou, Rennes, Ile Et Vilaine, France
Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 50
- Registration Number
- NCT03823079
Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas
- Conditions
- Interventions
- First Posted Date
- 2019-01-09
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 76
- Registration Number
- NCT03797625
- Locations
- 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 95
- Registration Number
- NCT03794349
- Locations
- 🇺🇸
Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸Yale University, New Haven, Connecticut, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRC
- First Posted Date
- 2019-01-03
- Last Posted Date
- 2019-01-03
- Target Recruit Count
- 100
- Registration Number
- NCT03792269
- Locations
- 🇨🇳
The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
FOLFIRINOX for 2nd-line Treatment of BTC
- Conditions
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Dong-A University Hospital
- Target Recruit Count
- 34
- Registration Number
- NCT03778593
- Locations
- 🇰🇷
Dong-A University Hospital, Busan, Korea, Republic of
Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma.
- Conditions
- Interventions
- First Posted Date
- 2018-12-12
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Lund University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT03773367
- Locations
- 🇳🇴
Oslo University Hospital, Ullevål Hospital, Oslo, Norway
🇸🇪Karolinska University Hospital, Stockholm, Sweden
🇸🇪Lund University Hospital, Lund, Sweden
Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal
- Conditions
- Interventions
- First Posted Date
- 2018-11-23
- Last Posted Date
- 2021-06-30
- Target Recruit Count
- 31
- Registration Number
- NCT03751176
- Locations
- 🇪🇸
ICO Girona Dr. Josep Trueta, Gerona, Barcelona, Spain
🇪🇸Hospital de Granollers, Granollers, Barcelona, Spain
🇪🇸Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain
Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas
- Conditions
- Interventions
- First Posted Date
- 2018-10-26
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 89
- Registration Number
- NCT03722108
- Locations
- 🇫🇷
Centre de Cancérologie du Grand Montpellier, Montpellier, France
🇫🇷CHU Dupuytren, Limoges, France
🇫🇷Clinique de Flandre, Coudekerque-Branche, France
FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2018-10-26
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 218
- Registration Number
- NCT03721653
- Locations
- 🇮🇹
Francesca Vannini, Pisa, Italia, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.